Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Clin Cancer Res. 2018 Feb 2;24(15):3681–3691. doi: 10.1158/1078-0432.CCR-17-2259

Figure 1. BQ323636.1 is overexpressed in tamoxifen resistant breast cancer cells.

Figure 1

A) mRNA expression of BQ323636.1 in different breast cell lines. qPCR was performed to determine the expression level of BQ in normal breast cell line (MCF-10A), Tamoxifen sensitive breast cancer cell lines (MCF-7 and ZR-75) and Tamoxifen resistant cell lines (LCC2 and AK-47). Actin was used as internal control. B) Protein expression of BQ323636.1 in Tamoxifen sensitive and resistant cell lines. Western blot was performed to determine the protein level of BQ323636.1. Actin was used as a loading control.

Overexpression of BQ323636.1 conferred Tamoxifen resistance in vitro and in vivo Overexpression of BQ323636.1 induced Tamoxifen resistance in the sensitive cell lines C) MCF-7 and D) ZR-75. The cells were treated with different concentration of Tamoxifen for 72 hours. MTT assay was performed to determine the cell viability. Samples were triplicated. E) Treatment of Tamoxifen could reduce xenograft tumor volume in control ZR-75 cells and as illustrated in the growth curve. The number of mice used in control group and treatment group were 4 and 4 respectively F) Overexpression of BQ323636.1 induced Tamoxifen resistance in vivo and as illustrated in the growth curve. The number of mice used in control group and treatment group were 4 and 5 respectively. % of tumor volume change was presented as mean ± s.d. Data was expressed as mean ± s.d from three independent experiments. * represents p<0.05; ** represents p<0.01; *** represent p<0.001. Statistical significance was determined by student T-Test.